Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma

Cell Cycle

Volumn 11, Issue 2, 2012, Pages 322-334

  Zhang, Chris Z Y ^a,b   Chen, George G ^a   Merchant, Juanita L ^c,d   Lai, Paul B S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; HCC; HDACi; p53 mutant; ZBP 89

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; MUTANT PROTEIN; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; ZBP 89; ZINC FINGER PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 84862974648     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.2.18758     Document Type: Article

References (41)

1. Zhou W, Zhu WG. The changing face of HDAC inhibitor depsipeptide. Curr Cancer Drug Targets 2009; 9:91-100; PMID:19200053; http://dx.doi.org/10.2174/ 156800909787314039.
2. Deubzer HE, Ehemann V, Westermann F, Heinrich R, Mechtersheimer G, Kulozik AE, et al. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008; 122:1891-900; PMID:18074352; http://dx.doi.org/10.1002/ijc.23295.
3. Bloemen JG, Venema K, van de Poll MC, Olde Damink SW, Buurman WA, Dejong CH. Short chain fatty acids exchange across the gut and liver in humans measured at surgery. Clin Nutr 2009; 28:657-61; PMID:19523724; http://dx.doi.org/10. 1016/j.clnu.2009.05.011.
4. Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004; 23:21-9; PMID:14712207; http://dx.doi.org/10.1038/sj.onc.1207020.
5. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95:6791-6; PMID:9618491; http://dx.doi.org/10.1073/pnas.95.12. 6791.
6. Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 2008; 68:9601-7; PMID:19047136; http://dx.doi.org/10.1158/0008-5472.CAN-07-5270.
7. Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002; 2:139-48; PMID:12204534; http://dx.doi.org/10.1016/S1535-6108(02)00095-8.
8. Zhang CZ, Chen GG, Lai PB. Transcription factor ZBP-89 in cancer growth and apoptosis. Biochim Biophys Acta 2010; 1806:36-41; PMID:20230874.
9. Bai L, Merchant JL. ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol 2001; 21:4670-83; PMID:11416144; http://dx.doi.org/10. 1128/MCB.21.14.4670-83.2001.
10. Bai L, Yoon SO, King PD, Merchant JL. ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ 2004; 11:663-73; PMID:14963412.
11. Law GL, Itoh H, Law DJ, Mize GJ, Merchant JL, Morris DR. Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter. J Biol Chem 1998; 273:19955-64; PMID:9685330; http://dx.doi.org/10.1074/jbc.273. 32.19955.
12. Merchant JL, Iyer GR, Taylor BR, Kitchen JR, Mortensen ER, Wang Z, et al. ZBP-89, a Kruppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol Cell Biol 1996; 16:6644-53; PMID:8943318.
13. Bai L, Kao JY, Law DJ, Merchant JL. Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection. Gastroenterology 2006; 131:841-52; PMID:16952553; http://dx.doi.org/10.1053/j. gastro.2006.06.014.
14. waf1 transcription in human cells. J Biol Chem 2000; 275:30725-33; PMID:10899165; http://dx.doi.org/10.1074/jbc.M004249200.
15. waf1 induction by butyrate. Biochem Biophys Res Commun 2007; 359:817-21; PMID:17560543; http://dx.doi.org/10.1016/j.bbrc.2007.05.197.
16. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137:609-22; PMID:19450511; http://dx.doi.org/10.1016/j.cell.2009.04.050.
17. Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, Box G, et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009; 29:2243-53; PMID:19223463; http://dx.doi.org/10.1128/MCB.00959-08.
18. Trinh DL, Elwi AN, Kim SW. Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosis. Oncotarget 2010; 1:396-404; PMID:21311096.
19. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9:701-13; PMID:19693097.
20. Okada M, Tessier A, Bai L, Merchant JL. p53 mutants suppress ZBP-89 function. Anticancer Res 2006; 26:2023-8; PMID:16827139.
21. Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, et al. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol 2003; 162:1823-9; PMID:12759240; http://dx.doi.org/10.1016/S0002-9440(10)64317-9.
22. Merchant JL, Bai L, Okada M. ZBP-89 mediates butyrate regulation of gene expression. J Nutr 2003; 133:2456-60; PMID:12840224.
23. Chen GG, Chan UP, Bai LC, Fung KY, Tessier A, To AK, et al. ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest. Cancer Lett 2009; 283:52-8; PMID:19362768; http://dx.doi.org/10.1016/j.canlet.2009.03.024.
24. Arts J, King P, Marien A, Floren W, Belien A, Janssen L, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009; 15:6841-51; PMID:19861438; http://dx.doi.org/10.1158/1078-0432.CCR-09- 0547.
25. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107:600-8; PMID:19459166; http://dx.doi.org/10. 1002/jcb.22185.
26. Cang S, Ma Y, Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2009; 2:22; PMID:19486511; http://dx.doi.org/10.1186/1756-8722-2-22.
27. Zhou GS, Liu SD, Zhang ZS, Zhang MJ, Li X, Wang YD, et al. Intrasplenic heterotransplantation of in vitro cultured human fetal hepatic stem cells for treatment of acute liver injury in mice with severe combined immunodeficiency. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27:817-20; PMID:17584646.
28. + T cells. Int Immunopharmacol 2009; 9:1289-97; PMID:19664724; http://dx.doi.org/10.1016/j.intimp.2009.07.012.
29. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223:116-26; PMID:21125670; http://dx.doi.org/10.1002/path.2784.
30. Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, et al. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 2010; 1:405-22; PMID:21311097.
31. Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007; 26:2243-54; PMID:17401433; http://dx.doi.org/10.1038/sj.onc.1210295.
32. Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010; 9:1847-55; PMID:20436301; http://dx.doi.org/10.4161/cc.9.9.11545.
33. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, et al. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011; 10:1679-89; PMID:21508668; http://dx.doi.org/10.4161/cc.10.10.15642.
34. Napoli M, Girardini JE, Piazza S, Del Sal G. Wiring the oncogenic circuitry: Pin1 unleashes mutant p53. Oncotarget 2011; 2:654-6; PMID:21926448.
35. Catasus L, Gallardo A, Cuatrecasas M, Prat J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009; 22:522-9; PMID:19234438; http://dx.doi.org/10.1038/modpathol. 2009.5.
36. Hasegawa T, Takeuchi A, Miyaishi O, Isobe K, de Crombrugghe B. Cloning and characterization of a transcription factor that binds to the proximal promoters of the two mouse type I collagen genes. J Biol Chem 1997; 272:4915-23; PMID:9030551; http://dx.doi.org/10.1074/jbc.272.8.4915.
37. Inazuka M, Tahira T, Horiuchi T, Harashima S, Sawabe T, Kondo M, et al. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology (Oxford) 2000; 39:262-6; PMID:10788533; http://dx.doi.org/10.1093/rheumatology/39.3.262.
38. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363-73; PMID:15837625; http://dx.doi.org/10.1016/j.ccr.2005.02.019.
39. Schuster A, Schilling T, De Laurenzi V, Koch AF, Seitz S, Staib F, et al. DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 2010; 9:2629-39; PMID:20581467; http://dx.doi.org/10.4161/cc.9.13.12110.
40. Bai L, Merchant JL. Transcription factor ZBP-89 is required for STAT1 constitutive expression. Nucleic Acids Res 2003; 31:7264-70; PMID:14654702; http://dx.doi.org/10.1093/nar/gkg929.
41. WAF1/CIP1 and contributes to its stability. Cell Cycle 2009; 8:889-95; PMID:19221506; http://dx.doi.org/10.4161/cc.8.6.7898.